Most of you will have heard about the approval of BLINCYTO® and VONVENDI – both drugs based in part on our partners’ intellectual property. These are the big moments in technology transfer: when the benefits to patients become tangible. However these wouldn’t be possible without the many small steps and minor successes along the way that often stay hidden.
This is just one reason why we have decided to compile for our partners and other interested parties an annual report on everything that we have initiated together, developed and achieved. At the same time, we would like to use the report to increase the transparency of our work.
For our 28 partners in 2015 we have
- examined 96 invention disclosures and accompanied 38 patent applications
- provided intensive support for 4 start-up projects and several project developments
- raised EUR 12.5 million in funding for translational development
- acquired equity in 3 companies and sold 3 portfolio companies/shareholdings
- distributed EUR 1.2 million to the LifeScience Foundation, mostly from the sale of equity
- negotiated 40 agreements with industry that have generated a total of EUR 9.5 million in revenues for our partners.
In 2015, products to which our partners have contributed generated a total turnover of more that EUR 2 billion, and our portfolio companies employed 200 staff.
Have a browse through the report! Apart from our figures and infographics, you can also find exciting examples of projects that demonstrate the potential benefit of our partners’ work to society.